Skip to main content

Insulet Corporation guidance

  • PODD · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$147.52+1.53%Close 17 Nov 2026 · Market value $10.26B

In its results release of 4 Nov 2026 (Q3 FY2026), Insulet Corporation gave 1 forecast in figures, among them EPS growth (adjusted) of +30% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
EPS growth · AdjustedFY2026+30%Adjusted EPS Growth 1 30%

Source: the company's earnings release.

Guidance against results above 2 · within 0 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS growth · AdjustedFY2026+30%Given once—To come
Gross marginFY2025About 71%Given once71.63%Above the range
Revenue growthQ1 FY2025+22% to +25%Given once+28.82%Above the range
Revenue growthFY2024+20% to +21%Given once+22.07%Above the range
Gross marginFY2024About 69%Given once69.79%Above the range
Revenue growthQ4 FY2024+12% to +15%Given once+17.2%Above the range

PODD in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.